[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0Fdlzgjg_s0uUf_xhbXQaTXTmBjGnM8bsDfl0oTOp8c":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"University of Glasgow",[4],140,false,16,7,562344,2,117,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Healthy",9,{"name":18,"count":19},"Sarcopenia",6,{"name":21,"count":22},"Exercise",5,{"name":24,"count":22},"Asthma",{"name":26,"count":27},"Spinal Cord Injury",4,{"name":29,"count":30},"Obesity",3,{"name":32,"count":30},"Lung Cancer",{"name":34,"count":30},"Cardiovascular Diseases",[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07299942","Impact of Beta-glucan Supplementation During Calorie and Carbohydrate-restricted Diet on Body Weight and Body Fat Loss, Appetite, and Gastrointestinal Appetite Hormones.","2025-01-31","Beta-glucan addition to a restricted calorie of meal replacements and carbohydrate diet.",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,75,93,143,161,188,206,231,258,297,319,345,372,390,416,439,457,475,493,511,536,554,578,604,622,645,669,692,716,744,767,793],{"intervention":40,"totalTrials":50,"cells":51},1,{"EARLY_PHASE1":52,"PHASE1":55,"PHASE2":57,"PHASE3":59,"PHASE4":61,"NA":63},{"trials":53,"activeCount":54},[],0,{"trials":56,"activeCount":54},[],{"trials":58,"activeCount":54},[],{"trials":60,"activeCount":54},[],{"trials":62,"activeCount":54},[],{"trials":64,"activeCount":50,"soonestReadout":39},[65],{"nctId":37,"briefTitle":38,"status":66,"phases":67,"primaryCompletion":39,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":73},"RECRUITING",[47],"2025-12-30","2024-07-01",60,[72],"Overweight and Obese Women",[40,74],"Cellulose (Placebo) addition to a restricted calorie of meal replacements and carbohydrate diet.",{"intervention":74,"totalTrials":50,"cells":76},{"EARLY_PHASE1":77,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":87},{"trials":78,"activeCount":54},[],{"trials":80,"activeCount":54},[],{"trials":82,"activeCount":54},[],{"trials":84,"activeCount":54},[],{"trials":86,"activeCount":54},[],{"trials":88,"activeCount":50,"soonestReadout":39},[89],{"nctId":37,"briefTitle":38,"status":66,"phases":90,"primaryCompletion":39,"completion":68,"start":69,"enrollment":70,"conditions":91,"interventions":92},[47],[72],[40,74],{"intervention":94,"totalTrials":30,"cells":95},"Rosiglitazone",{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":118,"NA":141},{"trials":97,"activeCount":54},[],{"trials":99,"activeCount":54},[],{"trials":101,"activeCount":54},[],{"trials":103,"activeCount":54},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":113},"NCT00119496","Rosiglitazone Versus Theophylline in Asthmatic Smokers","COMPLETED",[44,45],"2007-06","2005-07",79,[24],[114,115,116,117],"rosiglitazone","theophylline","beclomethasone","inhaled beclomethasone and oral theophylline",{"trials":119,"activeCount":54},[120,130],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"enrollment":70,"conditions":125,"interventions":128},"NCT00225342","Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina","WITHDRAWN",[46],[126,127],"Angina Pectoris","Diabetes Mellitus, Type 2",[94,129],"Gliclazide",{"nctId":131,"briefTitle":132,"status":133,"phases":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT00225355","Rosiglitazone Versus Placebo in Chronic Stable Angina","TERMINATED",[46],"2006-11","2006-02",80,[126,139],"Metabolic Syndrome X",[94],{"trials":142,"activeCount":54},[],{"intervention":129,"totalTrials":50,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":159},{"trials":146,"activeCount":54},[],{"trials":148,"activeCount":54},[],{"trials":150,"activeCount":54},[],{"trials":152,"activeCount":54},[],{"trials":154,"activeCount":54},[155],{"nctId":121,"briefTitle":122,"status":123,"phases":156,"enrollment":70,"conditions":157,"interventions":158},[46],[126,127],[94,129],{"trials":160,"activeCount":54},[],{"intervention":162,"totalTrials":50,"cells":163},"etanercept or adalimumab",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":186},{"trials":165,"activeCount":54},[],{"trials":167,"activeCount":54},[],{"trials":169,"activeCount":54},[],{"trials":171,"activeCount":54},[],{"trials":173,"activeCount":54},[174],{"nctId":175,"briefTitle":176,"status":107,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},"NCT01021735","Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy",[46],"2014-12","2015-04","2010-04",302,[183],"Rheumatoid Arthritis",[162,185],"Rituximab",{"trials":187,"activeCount":54},[],{"intervention":185,"totalTrials":50,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":204},{"trials":191,"activeCount":54},[],{"trials":193,"activeCount":54},[],{"trials":195,"activeCount":54},[],{"trials":197,"activeCount":54},[],{"trials":199,"activeCount":54},[200],{"nctId":175,"briefTitle":176,"status":107,"phases":201,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":202,"interventions":203},[46],[183],[162,185],{"trials":205,"activeCount":54},[],{"intervention":207,"totalTrials":50,"cells":208},"Duraphat® Fluoride Varnish",{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":217,"NA":229},{"trials":210,"activeCount":54},[],{"trials":212,"activeCount":54},[],{"trials":214,"activeCount":54},[],{"trials":216,"activeCount":54},[],{"trials":218,"activeCount":54},[219],{"nctId":220,"briefTitle":221,"status":107,"phases":222,"primaryCompletion":223,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT01674933","Fluoride Varnish For Childsmile Nursery School Attenders",[46],"2017-08-31","2012-10",1610,[227],"Dental Caries",[207],{"trials":230,"activeCount":54},[],{"intervention":232,"totalTrials":50,"cells":233},"Ferric Derisomaltose",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":256},{"trials":235,"activeCount":54},[],{"trials":237,"activeCount":54},[],{"trials":239,"activeCount":54},[],{"trials":241,"activeCount":54},[],{"trials":243,"activeCount":54},[244],{"nctId":245,"briefTitle":246,"status":107,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":255},"NCT02642562","Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN",[46],"2022-08-26","2016-08",1160,[252,253,254],"Chronic Heart Failure","Iron Deficiency","Left Ventricular Systolic Dysfunction",[232],{"trials":257,"activeCount":54},[],{"intervention":259,"totalTrials":11,"cells":260},"carboplatin",{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":279,"PHASE4":293,"NA":295},{"trials":262,"activeCount":54},[],{"trials":264,"activeCount":54},[],{"trials":266,"activeCount":54},[267],{"nctId":268,"briefTitle":269,"status":107,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT01229930","Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery",[44],"2012-12","2010-06",130,[275],"Cervical Cancer",[259,277,278],"cediranib maleate","paclitaxel",{"trials":280,"activeCount":54},[281],{"nctId":282,"briefTitle":283,"status":107,"phases":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":291},"NCT00003998","Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer",[45],"2004-12","1998-10",1050,[289,290],"Ovarian Cancer","Primary Peritoneal Cavity Cancer",[259,292,278],"docetaxel",{"trials":294,"activeCount":54},[],{"trials":296,"activeCount":54},[],{"intervention":278,"totalTrials":11,"cells":298},{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":309,"PHASE4":315,"NA":317},{"trials":300,"activeCount":54},[],{"trials":302,"activeCount":54},[],{"trials":304,"activeCount":54},[305],{"nctId":268,"briefTitle":269,"status":107,"phases":306,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":307,"interventions":308},[44],[275],[259,277,278],{"trials":310,"activeCount":54},[311],{"nctId":282,"briefTitle":283,"status":107,"phases":312,"completion":285,"start":286,"enrollment":287,"conditions":313,"interventions":314},[45],[289,290],[259,292,278],{"trials":316,"activeCount":54},[],{"trials":318,"activeCount":54},[],{"intervention":320,"totalTrials":50,"cells":321},"ketamine hydrochloride",{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":341,"NA":343},{"trials":323,"activeCount":54},[],{"trials":325,"activeCount":54},[],{"trials":327,"activeCount":54},[],{"trials":329,"activeCount":54},[330],{"nctId":331,"briefTitle":332,"status":333,"phases":334,"primaryCompletion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},"NCT01316744","Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain","UNKNOWN",[45],"2011-10","2009-04",214,[339],"Cancer",[320],{"trials":342,"activeCount":54},[],{"trials":344,"activeCount":54},[],{"intervention":346,"totalTrials":50,"cells":347},"chemotherapy",{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":368,"NA":370},{"trials":349,"activeCount":54},[],{"trials":351,"activeCount":54},[],{"trials":353,"activeCount":54},[],{"trials":355,"activeCount":54},[356],{"nctId":357,"briefTitle":358,"status":107,"phases":359,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":366},"NCT00416897","Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure",[45],"2008-12","2003-03",280,[364,365],"Multiple Myeloma and Plasma Cell Neoplasm","Renal Failure",[346,367],"dexamethasone",{"trials":369,"activeCount":54},[],{"trials":371,"activeCount":54},[],{"intervention":367,"totalTrials":50,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":386,"NA":388},{"trials":375,"activeCount":54},[],{"trials":377,"activeCount":54},[],{"trials":379,"activeCount":54},[],{"trials":381,"activeCount":54},[382],{"nctId":357,"briefTitle":358,"status":107,"phases":383,"completion":360,"start":361,"enrollment":362,"conditions":384,"interventions":385},[45],[364,365],[346,367],{"trials":387,"activeCount":54},[],{"trials":389,"activeCount":54},[],{"intervention":391,"totalTrials":50,"cells":392},"Metformin",{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":412,"NA":414},{"trials":394,"activeCount":54},[],{"trials":396,"activeCount":54},[],{"trials":398,"activeCount":54},[],{"trials":400,"activeCount":54},[401],{"nctId":402,"briefTitle":403,"status":107,"phases":404,"primaryCompletion":405,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":411},"NCT01483560","REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)",[45],"2017-03-19","2017-04-18","2011-12",493,[410],"Diabetes Mellitus, Type 1",[391],{"trials":413,"activeCount":54},[],{"trials":415,"activeCount":54},[],{"intervention":417,"totalTrials":50,"cells":418},"Atorvastatin",{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":435,"NA":437},{"trials":420,"activeCount":54},[],{"trials":422,"activeCount":54},[],{"trials":424,"activeCount":54},[],{"trials":426,"activeCount":54},[427],{"nctId":428,"briefTitle":429,"status":107,"phases":430,"primaryCompletion":431,"completion":431,"start":110,"enrollment":432,"conditions":433,"interventions":434},"NCT00126048","Trial to Evaluate the Effect of Statins on Asthma Control of Patients With Chronic Asthma",[44,45],"2007-09",54,[24],[417],{"trials":436,"activeCount":54},[],{"trials":438,"activeCount":54},[],{"intervention":292,"totalTrials":50,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":453,"NA":455},{"trials":442,"activeCount":54},[],{"trials":444,"activeCount":54},[],{"trials":446,"activeCount":54},[],{"trials":448,"activeCount":54},[449],{"nctId":282,"briefTitle":283,"status":107,"phases":450,"completion":285,"start":286,"enrollment":287,"conditions":451,"interventions":452},[45],[289,290],[259,292,278],{"trials":454,"activeCount":54},[],{"trials":456,"activeCount":54},[],{"intervention":115,"totalTrials":50,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":471,"NA":473},{"trials":460,"activeCount":54},[],{"trials":462,"activeCount":54},[],{"trials":464,"activeCount":54},[],{"trials":466,"activeCount":54},[467],{"nctId":105,"briefTitle":106,"status":107,"phases":468,"completion":109,"start":110,"enrollment":111,"conditions":469,"interventions":470},[44,45],[24],[114,115,116,117],{"trials":472,"activeCount":54},[],{"trials":474,"activeCount":54},[],{"intervention":116,"totalTrials":50,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":489,"NA":491},{"trials":478,"activeCount":54},[],{"trials":480,"activeCount":54},[],{"trials":482,"activeCount":54},[],{"trials":484,"activeCount":54},[485],{"nctId":105,"briefTitle":106,"status":107,"phases":486,"completion":109,"start":110,"enrollment":111,"conditions":487,"interventions":488},[44,45],[24],[114,115,116,117],{"trials":490,"activeCount":54},[],{"trials":492,"activeCount":54},[],{"intervention":117,"totalTrials":50,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":507,"NA":509},{"trials":496,"activeCount":54},[],{"trials":498,"activeCount":54},[],{"trials":500,"activeCount":54},[],{"trials":502,"activeCount":54},[503],{"nctId":105,"briefTitle":106,"status":107,"phases":504,"completion":109,"start":110,"enrollment":111,"conditions":505,"interventions":506},[44,45],[24],[114,115,116,117],{"trials":508,"activeCount":54},[],{"trials":510,"activeCount":54},[],{"intervention":512,"totalTrials":50,"cells":513},"Insulin",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":515,"activeCount":54},[],{"trials":517,"activeCount":54},[],{"trials":519,"activeCount":54},[520],{"nctId":521,"briefTitle":522,"status":107,"phases":523,"start":524,"enrollment":525,"conditions":526,"interventions":529},"NCT00124826","SELESTIAL: Trial of Insulin to Control Blood Sugar After Acute Stroke Using Magnetic Resonance Imaging (MRI) End-Points",[44],"2004-05",45,[527,528],"Acute Stroke","Hyperglycemia",[512],{"trials":531,"activeCount":54},[],{"trials":533,"activeCount":54},[],{"trials":535,"activeCount":54},[],{"intervention":277,"totalTrials":50,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":539,"activeCount":54},[],{"trials":541,"activeCount":54},[],{"trials":543,"activeCount":54},[544],{"nctId":268,"briefTitle":269,"status":107,"phases":545,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":546,"interventions":547},[44],[275],[259,277,278],{"trials":549,"activeCount":54},[],{"trials":551,"activeCount":54},[],{"trials":553,"activeCount":54},[],{"intervention":555,"totalTrials":50,"cells":556},"doxorubicin-HPMA conjugate",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":558,"activeCount":54},[],{"trials":560,"activeCount":54},[],{"trials":562,"activeCount":54},[563],{"nctId":564,"briefTitle":565,"status":333,"phases":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT00003165","Doxorubicin in Treating Women With Advanced Breast Cancer",[44],"1997-12",25,[570],"Breast Cancer",[555],{"trials":573,"activeCount":54},[],{"trials":575,"activeCount":54},[],{"trials":577,"activeCount":54},[],{"intervention":579,"totalTrials":50,"cells":580},"Ambrisentan",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":582,"activeCount":54},[],{"trials":584,"activeCount":54},[],{"trials":586,"activeCount":54},[587],{"nctId":588,"briefTitle":589,"status":333,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":596},"NCT01617746","Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma",[44],"2014-05","2015-12","2012-11",18,[24],[579,597],"Bosentan",{"trials":599,"activeCount":54},[],{"trials":601,"activeCount":54},[],{"trials":603,"activeCount":54},[],{"intervention":597,"totalTrials":50,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":607,"activeCount":54},[],{"trials":609,"activeCount":54},[],{"trials":611,"activeCount":54},[612],{"nctId":588,"briefTitle":589,"status":333,"phases":613,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":614,"interventions":615},[44],[24],[579,597],{"trials":617,"activeCount":54},[],{"trials":619,"activeCount":54},[],{"trials":621,"activeCount":54},[],{"intervention":623,"totalTrials":50,"cells":624},"bryostatin 1",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":626,"activeCount":54},[],{"trials":628,"activeCount":54},[],{"trials":630,"activeCount":54},[631],{"nctId":632,"briefTitle":633,"status":107,"phases":634,"completion":635,"start":636,"conditions":637,"interventions":638},"NCT00004008","Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer",[44],"2003-05","1999-07",[289],[623],{"trials":640,"activeCount":54},[],{"trials":642,"activeCount":54},[],{"trials":644,"activeCount":54},[],{"intervention":646,"totalTrials":50,"cells":647},"vadimezan",{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":649,"activeCount":54},[],{"trials":651,"activeCount":54},[652],{"nctId":653,"briefTitle":654,"status":107,"phases":655,"completion":656,"start":657,"enrollment":30,"conditions":658,"interventions":660},"NCT00003697","Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors",[43],"1998-12","1995-10",[659],"Unspecified Adult Solid Tumor, Protocol Specific",[646],{"trials":662,"activeCount":54},[],{"trials":664,"activeCount":54},[],{"trials":666,"activeCount":54},[],{"trials":668,"activeCount":54},[],{"intervention":670,"totalTrials":50,"cells":671},"mureletecan",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":673,"activeCount":54},[],{"trials":675,"activeCount":54},[676],{"nctId":677,"briefTitle":678,"status":333,"phases":679,"start":680,"enrollment":681,"conditions":682,"interventions":683},"NCT00004076","PNU 166148 in Treating Patients With Metastatic Solid Tumors",[43],"1999-06",30,[659],[670],{"trials":685,"activeCount":54},[],{"trials":687,"activeCount":54},[],{"trials":689,"activeCount":54},[],{"trials":691,"activeCount":54},[],{"intervention":693,"totalTrials":50,"cells":694},"fosbretabulin disodium",{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":696,"activeCount":54},[],{"trials":698,"activeCount":54},[699],{"nctId":700,"briefTitle":701,"status":107,"phases":702,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":707},"NCT00003698","Chemotherapy in Treating Patients With Solid Tumors",[43],"2003-12","1998-07",35,[659],[693],{"trials":709,"activeCount":54},[],{"trials":711,"activeCount":54},[],{"trials":713,"activeCount":54},[],{"trials":715,"activeCount":54},[],{"intervention":717,"totalTrials":50,"cells":718},"oral steroid-dexamethasone",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":720,"activeCount":54},[],{"trials":722,"activeCount":54},[],{"trials":724,"activeCount":54},[],{"trials":726,"activeCount":54},[],{"trials":728,"activeCount":54},[],{"trials":730,"activeCount":54},[731],{"nctId":732,"briefTitle":733,"status":107,"phases":734,"primaryCompletion":735,"completion":736,"start":737,"enrollment":738,"conditions":739,"interventions":743},"NCT00411320","Determinants of Corticosteroid Insensitivity in Smokers With Asthma",[47],"2010-08","2010-09","2007-01",53,[24,740,741,742],"Smoking","Steroid Resistance","Corticosteroid Insensitivity",[717],{"intervention":745,"totalTrials":50,"cells":746},"Imiquimod cream",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":755,"NA":757},{"trials":748,"activeCount":54},[],{"trials":750,"activeCount":54},[],{"trials":752,"activeCount":54},[],{"trials":754,"activeCount":54},[],{"trials":756,"activeCount":54},[],{"trials":758,"activeCount":54},[759],{"nctId":760,"briefTitle":761,"status":333,"phases":762,"enrollment":763,"conditions":764,"interventions":766},"NCT00463359","A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base",[47],50,[765],"Basal Cell Carcinoma",[745],{"intervention":768,"totalTrials":50,"cells":769},"caloric restrction high carbohydrate low fat diet with exercise training program",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":771,"activeCount":54},[],{"trials":773,"activeCount":54},[],{"trials":775,"activeCount":54},[],{"trials":777,"activeCount":54},[],{"trials":779,"activeCount":54},[],{"trials":781,"activeCount":54},[782],{"nctId":783,"briefTitle":784,"status":333,"phases":785,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT06022315","Impact of Macronutrient Composition of Energy-restricted Diet and Exercise on Body Composition and Appetite Hormones.",[47],"2024-12","2023-09-03",40,[790],"Gastrointestinal Hormones",[768,792],"caloric restrction high fat low carbohydrate diet with exercise training program",{"intervention":792,"totalTrials":50,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":796,"activeCount":54},[],{"trials":798,"activeCount":54},[],{"trials":800,"activeCount":54},[],{"trials":802,"activeCount":54},[],{"trials":804,"activeCount":54},[],{"trials":806,"activeCount":54},[807],{"nctId":783,"briefTitle":784,"status":333,"phases":808,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":809,"interventions":810},[47],[790],[768,792]]